Next-generation sequencing of central nervous systems tumors: the future of personalized patient management.

Leomar Y Ballester, Adriana Olar, Sinchita Roy-Chowdhuri

Abstract readEditorialComment

In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Leveraging single-cell sequencing to classify and characterize tumor subgroups in bulk RNA-sequencing data.Journal of neuro-oncology · 2024
Article
Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies.Science advances · 2022
Article
Genetic Factors Affecting Intraoperative 5-aminolevulinic Acid-induced Fluorescence of Diffuse Gliomas.Radiology and oncology · 2017
Article

4 · The record

Corrections and comments

Comment on
Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.2016

5 · Who and what money

Authors and funding

3 authors.

Leomar Y BallesterDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (L.Y.B.); Department of Hematopathology, Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.O.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.R.-C.).

Adriana OlarDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (L.Y.B.); Department of Hematopathology, Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.O.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.R.-C.).

Sinchita Roy-ChowdhuriDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (L.Y.B.); Department of Hematopathology, Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.O.); Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.R.-C.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

High-Throughput Nucleotide SequencingPrecision MedicineCentral Nervous System NeoplasmsHumans

Identifiers

PMID26917589

DOI10.1093/neuonc/nov329

PMCPMC4767248

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.